May 15, 2018   SOURCE: PR NewsWire

Peripheral T-Cell Lymphoma (PTCL) Market Spotlight - Forecast to 2025

Peripheral T-Cell Lymphoma (PTCL) Market Spotlight - Forecast to 2025

DUBLIN, May 15, 2018 /PRNewswire/ --

The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

    --  The author estimates that in 2016, there were approximately 17,800
        incident cases of peripheral T-cell lymphoma worldwide, and forecasts
        that number to increase to 21,300 incident cases by 2025.
    --  It is estimated that the majority of diagnosed cases were in males in
        2016.
    --  The incidence of peripheral T-cell lymphoma is highest among individuals
        aged 60-79 years. The approved drugs for peripheral T-cell lymphoma
        target histone deacetylase, purine nucleoside phosphorylase,
        dihydrofolate reductase, and chemokine receptor 4. The majority of
        approved therapies are administered via the intravenous route; however,
        two products are available in oral formulations.
    --  The majority of industry-sponsored drugs in active clinical development
        for peripheral T-cell lymphoma are in Phase II, with only two drugs in
        Phase III.
    --  Therapies in the pipeline for peripheral T-cell lymphoma focus on a wide
        variety of targets. The majority of pipeline drugs in development are
        administered intravenously, with a smaller number being tested in oral
        formulations.
    --  High impact upcoming events in the peripheral T-cell lymphoma space
        comprise topline Phase IIa and Phase III trial results for ALRN-6924 and
        Adcetris, respectively.
    --  There have been 10 licensing and asset acquisition deals involving
        peripheral T-cell lymphoma drugs during 2013-18. The largest deal was
        the October 2017 $190m exclusive licensing agreement between Karyopharm
        and Ono Pharmaceutical for the development and marketing of Karyopharm's
        selinexor and KPT-8602 in South Korea, Hong Kong, Taiwan, Japan, and
        ASEAN countries.
    --  Istodax's polymorph patent is set to expire in 2021, which will open the
        door to generic entry. Istodax sales ranked highest among drugs
        indicated for peripheral T-cell lymphoma during 2012-17, and it is
        expected to retain the top spot through the forecast period.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        vast majority of trials for peripheral T-cell lymphoma have been in the
        early and mid-phases of development, with 93% of trials in Phase I-II,
        and only 7% in Phase III-IV.
    --  The US has a substantial lead in the number of peripheral T-cell
        lymphoma clinical trials globally. The UK leads the major EU markets,
        while Japan has the top spot in Asia.
    --  Clinical trial activity in the peripheral T-cell lymphoma space is
        dominated by completed trials. Celgene has the highest number of
        completed clinical trials for peripheral T-cell lymphoma, with eight
        trials.
    --  Celgene leads industry sponsors with by far the highest number of
        clinical trials for peripheral T-cell lymphoma, followed by Spectrum
        Pharmaceuticals and Eisai.

For more information about this report visit https://www.researchandmarkets.com/research/98k3j2/peripheral_tcell?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/peripheral-t-cell-lymphoma-ptcl-market-spotlight---forecast-to-2025-300648461.html

SOURCE Research and Markets